CCL5 and sarcoma: Consistent with this, doxorubicin treatment caused a significant increase in cytoplasmic DNA levels in STS cells (Figure 1B), resulting in the upregulation of STING at the protein level and increased expression of type I IFN signature genes, including Ccl5, Cxcl10, and Ifnb1 in mouse sarcoma cells, and CCL5, CXCL10, IFNB1 in human sarcoma cells (Figure 1C, and Supplementary Figures 1B, C).